SEC Form 4 · accession 0001209191-19-002669
IMMUNE DESIGN CORP. · IMDZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sergey Yurasov
Officer — Sr. VP, Clinic. Devel. & CMO
Period of report
Jan 3, 2019
Accepted (ET)
Jan 7, 2019 · 8:34 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001437786
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 3, 2019 | A | 25,000 | $0.00 | A | 82,278 | D | |
| Common StockF4 | Jan 7, 2019 | S | 3,522 | $1.5717 | D | 78,756 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5 | $1.31 | Jan 3, 2019 | A | 110,000 | A | — | Jan 3, 2029 | Common Stock | 110,000 | 110,000 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of Immune Design Corp. common stock.
- F2Restricted stock unit shall vest in a series of three equal consecutive annual installments beginning on January 4, 2020, subject to the Reporting Person's continuous service through each such date.
- F3The shares were sold pursuant to a Rule 10b5-1 trading plan that was included in the Reporting Person's restricted stock unit agreements, dated January 4, 2017 and January 4, 2018, in order to satisfy a tax liability incurred upon the vesting of restricted stock units on January 4, 2019.
- F4The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.5635 to $1.621 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5One quarter of the shares underlying the option will vest on January 3, 2020, and the remainder of the shares underlying the option will vest at a rate of 1/24th per month thereafter, subject to the Reporting Person's continuous service through each such date.